Avecho Biotechnology (ASX:AVE) - Stock Price, News & Analysis

AVE Stock Overview

AVE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Makes less than USD$1m in revenue (A$474K)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Earnings have declined by 19.8% per year over past 5 years

+ 1 more risk

Avecho Biotechnology Limited Competitors

Nyrada

ASX:NYR

AU$17.4m

Argent BioPharma

ASX:RGT

AU$18.6m

Rhinomed

ASX:RNO

AU$11.5m

Emyria

ASX:EMD

AU$20.5m

Price History & Performance

Summary of all time highs, changes and price drops for Avecho Biotechnology
Historical stock prices
Current Share Price	AU$0.005
52 Week High	AU$0.009
52 Week Low	AU$0.003
Beta	2.03
1 Month Change	66.67%
3 Month Change	42.86%
1 Year Change	0%
3 Year Change	-75.00%
5 Year Change	42.86%
Change since IPO	-98.96%

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Shareholder Returns

	AVE	AU Pharmaceuticals	AU Market
7D	25.0%	-3.0%	-2.2%
1Y	0%	37.1%	4.5%

Return vs Industry: AVE underperformed the Australian Pharmaceuticals industry which returned 32.4% over the past year.

Return vs Market: AVE underperformed the Australian Market which returned 4% over the past year.

Price Volatility

Is AVE's price volatile compared to industry and market?
AVE volatility
AVE Average Weekly Movement	36.2%
Pharmaceuticals Industry Average Movement	11.1%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: AVE's share price has been volatile over the past 3 months.

Volatility Over Time: AVE's weekly volatility (36%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
1992	n/a	Paul Gavin	avecho.com.au

Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.

Avecho Biotechnology Limited Fundamentals Summary

How do Avecho Biotechnology's earnings and revenue compare to its market cap?
AVE fundamental statistics
Market cap	AU$15.85m
Earnings (TTM)	-AU$3.44m
Revenue (TTM)	AU$473.55k

33.5x

P/S Ratio

-4.6x

P/E Ratio

Is AVE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVE income statement (TTM)
Revenue	AU$473.55k
Cost of Revenue	AU$517.35k
Gross Profit	-AU$43.79k
Other Expenses	AU$3.39m
Earnings	-AU$3.44m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0011
Gross Margin	-9.25%
Net Profit Margin	-725.70%
Debt/Equity Ratio	0%

How did AVE perform over the long term?

See historical performance and comparison

AVE Stock Overview

Rewards

Risk Analysis

Avecho Biotechnology Limited Competitors

ASX:NYR

AU$17.4m

ASX:RGT

AU$18.6m

ASX:RNO

AU$11.5m

ASX:EMD

AU$20.5m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Recent updates

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth